News Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E. Other stock markets 02:10:55 2024-04-23 am EDT			5-day change	1st Jan Change
0.385 ^AUD	+8.45%		+6.94%	+11.59%

Apr. 18	Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	CI
Apr. 18	Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	Apr. 18	AQ
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18	CI
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Apr. 18	PU
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	Apr. 18	MT
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	Apr. 17	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	AQ
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	Apr. 16	MT
Immutep : Corporate Presentation	Mar. 26	PU
Encouraging results for Immutep's cancer therapies	Mar. 25	FI
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	Mar. 05	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Mar. 05	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	Mar. 05	AQ
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	Mar. 05	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	Feb. 27	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immutep Quarterly Activities Report Q2 FY24	Jan. 30	AQ
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	Jan. 04	CI
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	Jan. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immutep Limited

Equities

IMM

AU000000IMM6

Summary

Filters